Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea flag South Korea · Delayed Price · Currency is KRW
28,700
+150 (0.53%)
At close: Mar 24, 2025, 3:30 PM KST

Hanall Biopharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Operating Revenue
138,944134,910109,995101,59488,602
Upgrade
Other Revenue
--0-0-0-
Upgrade
Revenue
138,944134,910109,995101,59488,602
Upgrade
Revenue Growth (YoY)
2.99%22.65%8.27%14.66%-18.30%
Upgrade
Cost of Revenue
65,73859,87048,12041,36438,027
Upgrade
Gross Profit
73,20675,04061,87660,23150,575
Upgrade
Selling, General & Admin
51,85047,52042,58638,47234,264
Upgrade
Research & Development
19,99323,94516,49810,4629,316
Upgrade
Other Operating Expenses
660.34669.45584.09605.75541.03
Upgrade
Operating Expenses
72,97573,29660,37050,13244,640
Upgrade
Operating Income
230.471,7431,50610,0995,935
Upgrade
Interest Expense
-70.97-63.86-21.88-25.48-16.01
Upgrade
Interest & Investment Income
490.321,2271,427719.842,145
Upgrade
Earnings From Equity Investments
-99.53-62.12-45.39--
Upgrade
Currency Exchange Gain (Loss)
-408.83349.6-600.15-115.9482.78
Upgrade
Other Non Operating Income (Expenses)
-203.55-1,067-228.48-745.8711,138
Upgrade
EBT Excluding Unusual Items
-62.072,1272,0379,93219,284
Upgrade
Gain (Loss) on Sale of Investments
331.431,121-124.34-177.44-
Upgrade
Gain (Loss) on Sale of Assets
-452.56-9.3216.99-1,052-14.29
Upgrade
Asset Writedown
--36.72---44.82
Upgrade
Pretax Income
-183.23,2031,9298,70219,225
Upgrade
Income Tax Expense
1,622-306.081,678-194.05-539.21
Upgrade
Net Income
-1,8053,509251.478,89619,765
Upgrade
Net Income to Common
-1,8053,509251.478,89619,765
Upgrade
Net Income Growth
-1295.23%-97.17%-54.99%3.08%
Upgrade
Shares Outstanding (Basic)
5151515151
Upgrade
Shares Outstanding (Diluted)
5151515151
Upgrade
Shares Change (YoY)
0.04%-0.24%-0.76%0.05%0.00%
Upgrade
EPS (Basic)
-35.5969.214.95173.74386.19
Upgrade
EPS (Diluted)
-35.5969.214.95173.74386.19
Upgrade
EPS Growth
-1298.63%-97.15%-55.01%3.08%
Upgrade
Free Cash Flow
7,71827,23122,434-3,766-1,633
Upgrade
Free Cash Flow Per Share
152.20537.18441.48-73.55-31.91
Upgrade
Gross Margin
52.69%55.62%56.25%59.29%57.08%
Upgrade
Operating Margin
0.17%1.29%1.37%9.94%6.70%
Upgrade
Profit Margin
-1.30%2.60%0.23%8.76%22.31%
Upgrade
Free Cash Flow Margin
5.56%20.18%20.39%-3.71%-1.84%
Upgrade
EBITDA
3,3514,9904,55812,8248,829
Upgrade
EBITDA Margin
2.41%3.70%4.14%12.62%9.96%
Upgrade
D&A For EBITDA
3,1213,2473,0532,7252,894
Upgrade
EBIT
230.471,7431,50610,0995,935
Upgrade
EBIT Margin
0.17%1.29%1.37%9.94%6.70%
Upgrade
Effective Tax Rate
--86.97%--
Upgrade
Advertising Expenses
3,2303,2873,0902,1121,889
Upgrade
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.